Related Experiment Video
Updated: Feb 26, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumonia and Streptococcus pneumoniae vaccine
Gyu-Lee Kim1, Seung-Han Seon1, Dong-Kwon Rhee2
1School of Pharmacy, Sungkyunkwan University, Suwon, 440-746, South Korea.
Abstract:
Pneumonia is an inflammatory disease of the lung, responsible for high morbidity and mortality worldwide. It is caused by bacteria, viruses, fungi, or other microorganisms. Streptococcus pneumoniae, a gram-positive bacterium with over 90 serotypes, is the most common causative agent. Moreover, comorbid factors including heart failure, renal disease, and pulmonary disease could increase the risk of pneumococcal pneumonia. Since the advent of the pneumococcal vaccine in the 1980s, the incidence of pneumonia has decreased significantly. However, current vaccines confer only limited protection against serotypes included in the vaccine. Thus, to overcome this limitation, new types of pneumococcal vaccines have been sought and under clinical trials. In this review, we discuss pneumonia and summarize the various types of pneumococcal vaccines in progress.
Insights
Pneumonia, a lung inflammation, causes significant global mortality. New vaccines are being developed to improve protection against Streptococcus pneumoniae beyond current vaccine limitations.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Vaccinology
Background:
- Pneumonia is a major global health concern, leading to high morbidity and mortality.
- Streptococcus pneumoniae is the most frequent bacterial cause, with over 90 identified serotypes.
- Comorbidities like heart failure and renal disease increase susceptibility to pneumococcal pneumonia.
Purpose of the Study:
- To review the current understanding of pneumonia.
- To summarize the development of novel pneumococcal vaccines.
- To address limitations of existing vaccines against Streptococcus pneumoniae.
Main Methods:
- Literature review of pneumonia and pneumococcal vaccines.
- Analysis of current vaccine efficacy and limitations.
- Overview of ongoing clinical trials for new vaccine candidates.
Main Results:
- Pneumococcal vaccines introduced in the 1980s have reduced pneumonia incidence.
- Current vaccines offer limited protection, primarily against specific serotypes.
- Several new pneumococcal vaccine types are under clinical investigation.
Conclusions:
- Despite progress, limitations in current pneumococcal vaccines necessitate further development.
- Ongoing research focuses on broader serotype coverage and enhanced efficacy.
- New vaccines hold promise for reducing the global burden of pneumococcal pneumonia.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology
01:51Vaccinations